Sr Director, CPP
Johnson and Johnson, New Jersey, United States
Navin Goyal is a Senior Director and Therapy Area Lead in the Clinical Pharmacology and Pharmacometrics (CPP) Group at Janssen Pharmaceuticals, a Johnson and Johnson company, supporting the cardiovascular, metabolism, retinal, pulmonary hypertension, and neuroscience therapy areas. In this role, he is responsible for applying clinical pharmacology principles and model-based approaches across all phases of drug discovery and development spanning from early clinical studies through registration. Dr. Goyal graduated from the Department of Pharmaceutics in College of Pharmacy at University of Florida, Gainesville. After graduation, he worked in the Clinical Pharmacology group at GSK before joining Janssen.
Dr Goyal has published his work across multiple therapy areas including respiratory, neuroscience, cardiovascular and infectious diseases. His research interests also include pediatric drug development and new modalities. In addition to the day job, he continues to mentor students interns, post-doctoral fellows and scientists within his group at Janssen and through external collaborations. Dr. Goyal is a Fellow of ACCP, currently serves on the ACCP Board of Regents, held Treasurer position on its Executive Committee, and co-chaired the 2020 ACCP Annual Meeting. He is currently the ACCP Publications Committee Chair. Dr Goyal is also an active ISoP member (International Society of Pharmacometrics), and chaired the 2020 ACoP Annual Meeting (American Conference on Pharmacometrics). He also chaired the ISoP Awards Committee (2022-2023).
Disclosure(s): Johnson & Johnson: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Wednesday, November 13, 2024
10:45 AM – 12:15 PM MST
